US site closures as Takeda restructures vaccines business
This article was originally published in Scrip
A fundamental restructuring of Takeda Pharmaceutical's vaccines operations will see the closure of three sites in the US as it consolidates operations in this market in the Boston area as part of a revised global network for the unit.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.